stopping a glp-1 new study finds that drugs could put your heart at risk New research shows heart benefits

The benefit of neoadjuvant-adjuvant pembrolizumab was seen across all subgroups of patients including those with BRAF pathogenic variants

!Safety note The FDA has reviewed reports of suicidal thoughts or actions with GLP-1 receptor agonists and, in 2026, requested removal of suicidal ideation and behavior warning language from affected GLP-1 labels after finding no increased risk

These postbiotics address key limitations of current TMAU therapies: they circumvent the safety risks of live probiotics, avoid dysbiosis from antibiotics, and outperform dietary restrictions in sustainability

They have what you might call an antagonistic relationship